A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Shire; Takeda
- 15 Jan 2019 Planned End Date changed from 16 May 2019 to 3 Jan 2020.
- 15 Jan 2019 Planned primary completion date changed from 16 May 2019 to 3 Jan 2020.
- 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.